Literature DB >> 15168117

Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance.

H R De Raeve1, P B Vermeulen, K Vanderkerken, A L Harris, E Van Marck.   

Abstract

The aim of the study was to compare the angiogenic status, potential qualitative differences in microvessels and carbonic anhydrase IX expression in bone-marrow (BM) metastases and different haematological tumours at time of diagnosis. The microvessel density (MVD), endothelial-cell proliferation (ECP) and carbonic anhydrase IX (CA IX) immunoreactivity were determined on 210 trephine biopsies from 57 patients with multiple myeloma (MM), 13 with acute myeloid leukaemia (AML), 48 with chronic myeloproliferative syndrome (CMPS), 26 with chronic lymphocytic leukaemia (CLL), 25 with epithelial BM metastases, 18 with monoclonal gammopathy of undetermined significance (MGUS) and from a control group composed of 23 patients without haematological neoplasm. There was an increased MVD and ECP in epithelial BM metastases, MM, AML, CMPS and in a part of CLL. While an ECP greater than 0 was detected in 72% of MM, 75% of CMPS and 92% of AML, it was invariably observed (100%) in the BM metastases. The absence of ECP together with a MVD comparable with the control group in our MGUS cases supports the view that MGUS is a pre-angiogenic condition. Qualitative differences in microvessels were associated with growth patterns in MM and CLL and were observed between the different entities of CMPS. In one-third of the epithelial BM metastases, there was a focal CA IX immunoreactivity, which was never observed in the haematological diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168117     DOI: 10.1007/s00428-004-1028-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  31 in total

Review 1.  Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us.

Authors:  Lynn Hlatky; Philip Hahnfeldt; Judah Folkman
Journal:  J Natl Cancer Inst       Date:  2002-06-19       Impact factor: 13.506

Review 2.  Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours.

Authors:  P B Vermeulen; G Gasparini; S B Fox; C Colpaert; L P Marson; M Gion; J A M Beliën; R M W de Waal; E Van Marck; E Magnani; N Weidner; A L Harris; L Y Dirix
Journal:  Eur J Cancer       Date:  2002-08       Impact factor: 9.162

3.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases.

Authors:  C C Wykoff; N J Beasley; P H Watson; K J Turner; J Pastorek; A Sibtain; G D Wilson; H Turley; K L Talks; P H Maxwell; C W Pugh; P J Ratcliffe; A L Harris
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

4.  Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast.

Authors:  C C Wykoff; N Beasley; P H Watson; L Campo; S K Chia; R English; J Pastorek; W S Sly; P Ratcliffe; A L Harris
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

Review 5.  Angiogenesis in acute and chronic leukemias.

Authors:  D J Dickson; P J Shami
Journal:  Leuk Lymphoma       Date:  2001 Sep-Oct

6.  Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.

Authors:  A Aguayo; H Kantarjian; T Manshouri; C Gidel; E Estey; D Thomas; C Koller; Z Estrov; S O'Brien; M Keating; E Freireich; M Albitar
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

7.  Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.

Authors:  S K Chia; C C Wykoff; P H Watson; C Han; R D Leek; J Pastorek; K C Gatter; P Ratcliffe; A L Harris
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

8.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.

Authors:  B Dankbar; T Padró; R Leo; B Feldmann; M Kropff; R M Mesters; H Serve; W E Berdel; J Kienast
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

9.  Evidence of increased angiogenesis in patients with acute myeloid leukemia.

Authors:  J W Hussong; G M Rodgers; P J Shami
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

10.  The expression of carbonic anhydrase II in hematological malignancies.

Authors:  Mari Leppilampi; Pirjo Koistinen; Eeva-Riitta Savolainen; Jokke Hannuksela; Anna-Kaisa Parkkila; Onni Niemelä; Silvia Pastoreková; Jaromir Pastorek; Abdul Waheed; William S Sly; Seppo Parkkila; Hannu Rajaniemi
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

View more
  3 in total

Review 1.  [Molecular and parametric imaging with iron oxides].

Authors:  L Matuszewski; B Tombach; W Heindel; C Bremer
Journal:  Radiologe       Date:  2007-01       Impact factor: 0.635

2.  Part of the multiple myeloma-associated microvessels is functionally connected to the systemic circulation: a study in the murine 5T33MM model.

Authors:  Hendrik R De Raeve; Kewal Asosingh; Eddie Wisse; Ben Van Camp; Eric Van Marck; Karin Vanderkerken
Journal:  Virchows Arch       Date:  2004-06-30       Impact factor: 4.064

3.  Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma.

Authors:  J Caers; E Menu; H De Raeve; D Lepage; E Van Valckenborgh; B Van Camp; E Alvarez; K Vanderkerken
Journal:  Br J Cancer       Date:  2008-06-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.